H. Paul Dorman

NanOlogy Names CEO as Its Tumor-Targeted Cancer Drugs Near Key Regulatory Milestones

by | Dec 30, 2025
The Fort Worth oncology company tapped former Salarius Pharmaceuticals CEO David Arthur to lead its push toward commercialization, including a planned IND for a rare pediatric brain cancer program.
MORE